Academia
University of Oxford researchers have begun clinical trials for a new vaccine that can potentially target a wide range of HIV variants.
Although the COVID-19 pandemic is waning in the U.S., it’s not completely over and there are some concerns, particularly with the delta variant, which originated in India. Here’s a look.
Eli Lilly and Novo Nordisk published their data in The Lancet Diabetes & Endocrinology and presented them at the ADA conference.
It’s been a week of promising news for cancer research, with two possible treatment modalities reporting positive results.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Research shows that cancer can fool immune cells, which normally repair the body, into actually helping develop the disease.
New research shows T cells can be engineered to migrate more effectively inside tumor microenvironments, raising hopes of reproducing the remarkable outcomes seen for certain hematological cancer patient subsets in broader populations and indications.
This week, the German drug company announced that it is closing the doors to its ‘innovation hub’ in Mission Bay.
A recent study conducted by Public Health England found that the available vaccines were “highly effective” at preventing hospitalization after two doses.
Besides providing a sense of hope for children with this devastating disease, this research could offer another clue toward unlocking the mystery behind other forms of ALS.
PRESS RELEASES